Evolving the Unwearable Collection
Boehringer Ingelheim will partner with the Fashion Institute of Technology in New York to introduce a fifth design as part of The Unwearable Collection™
Search
Innovation in Medicinal Chemistry: Unlocking Unsolved Diseases
Innovation in Medicinal Chemistry: Unlocking Unsolved Diseases
Making Toys for Shelter Animals | Boehringer Ingelheim US
Find out how nearly 400 Boehringer Ingelheim employees came together to make toys out of donated t-shirts for animals living in shelters across the USA.
Science Stories
Science Stories
Trends & Insights
News
Leadership insights about our focus on patient centricity
Read about our patient-centric approach in discovering and developing medicines that transform patients’ lives from the point of view of Keri Yale, our head of patient centricity and engagement
Animal Health
Companion Animals, Horse Pets and Equines
First half 2019: High levels of investment in R&D and robust organic growth
First half 2019: High levels of investment in R&D and robust organic growth
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
Currency-adjusted net sales rose by 9.7 percent to 13.5 billion USD.
Galym Zhunisbekov
Galym Zhunisbekov, a Regional Regulatory Affairs Manager in Eastern Europe, talks about our philosophy and impact on patients’ lives.
Skin and Inflammatory Diseases
skin diseases
Code of Conduct
Our Code of Conduct sets the ethical standards that guides all our business activities. It´s about all of us. Each individual plays a vital role in bringing the Code of Conduct to live.
Focus on Alliance Management
Focus on Alliance Management
Partnering for Innovative Pet Therapeutics
Partnering for Innovative Pet Therapeutics
Biosimilars
: A biosimilar is a version of a biologic medication that is made by a different company than the one that invented it, with no clinically meaningful differences in terms of safety, potency and purity.
Animal Health | COVID-19 | Boehringer Ingelheim US
Click here to read more on how the COVID-19 pandemic has impacted the daily lives of veterinarians, livestock producers and others.
Brigitte Fuhr
Our data transformation
Work life balance
It is important that employees have a balance between professional and personal lives, so we offer various leave options and flexible working schedules.
Financial year 2018
Financial year 2018
Oncology Partnering Interests | Boehringer Ingelheim US
Click here to view our range of downloads on Boehringer Ingelheim's oncology & cancer immunology partnering interests.
Biosimilar Candidate to Humira® Accepted For Review | BI US
Boehringer Ingelheim announced today that its adalimumab biosimilar candidate to Humira®, has been accepted for regulatory review by the EMA and the FDA.
Corporate Social Responsibility | Boehringer Ingelheim US
Boehringer Ingelheim has a strong and longstanding commitment to improving the health of people and animals, both around the world and in local communities.
Contact Us
Contact Us
Our Responsibility
Our Responsibility
Life Forward
In everything we do we can shape and influence the future for the better: Learn more about “Life forward” and how our innovations improve lives.